Second IGWG Meeting
November 5-10, 2007
KEI Documents
November 9, 2007. Malini Aisola. Reasons Why the IGWG Should Not Place Limits on the Scope of Disease.
Search Results for: ustr
Comments on the IGWG II bis
Thiru Balasubramaniam, Geneva Representative, Knowledge Ecology International
Sara Crager, MD/PhD Candidate '12 at Yale University/Universities Allied for Essential Medicines
Nicoletta Dentico, Policy and Advocacy Advisor, DNDi
Survey of Patent Pools Demonstrates Variety of Purposes and Management Structures
Tuesday, 05 June 2007
An pdf version of this document is available here.
KEI Research Note 2007:6
David Serafino[1]
Knowledge Ecology International
4 June 2007
Table of Contents
EMILA Working Plan
Saturday, 02 June 2007
The Essential Medical Inventions Licensing Agency
Working Plan, June 1, 2007
Introduction
IGWG Briefing Paper on Patent Pools
Sunday, 03 June 2007
IGWG Briefing Paper on Patent Pools
Collective Management of Intellectual Property — The use of Patent Pools to expand access to essential medical technologies
KEI Research Note 2007:3 (1)
Notes on the Bayh-Dole Act of 1980
Sep 2, 2009 The Bayh-Dole Act (or University and Small Business Patent Procedures Act) was originally enacted in 1980 as Public Law 96-517, and was amended in 1984 by Public Law 98-620. Among other things, the Bayh-Dole Act was designed… Continue Reading
Sept 10: Scope of Patentable Subject Matter, Bilski ruling
KEI is hosting a brownbag lunch to discuss the scope of patentable subject matter with reference to the Supreme Court's forthcoming decision on Bilski's appeal.
Abbott sought compulsory license in 2007 US patent dispute
Sunday, 29 April 2007
(When the shoe was on the other foot, Abbott asked for a compulsory license, while criticizing Thailand for issuing compulsory licenses)
On the 12th of January 2007, Abbott Laboratories lost a bid in a U.S. District Court (the Western District of Wisconsin) for a compulsory license on a patent held by Innogenetics, Inc. that a judge and jury said Abbott infringed to manufacture and sell Hepatitis C virus (HCV) genotyping test kits.
Novartis (NVS): Some Examples of Joint Ventures, Partnerships, and Alliances
Wednesday, 29 August 2007
According to the Novartis strategic alliances webpage, the company is engaged in "More than 400 collaborations in over 20 countries, over 120 collaborations with major biotech companies, and over 280 collaborations with academic centers."
Selected Joint Ventures, Partnerships, and Alliances with Big Pharma
Novartis and Bayer Schering AG – PTK/ZK – These two companies initially collaborated in the devel Continue Reading
Bayer Healthcare (BAY): Select Joint Ventures, Partnerships, and Alliances
Thursday, 06 September 2007